ING sets EUR 304.00 target for UCB stock with 48.87 percent upside

Published on 10/13/2026 at 13:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

BIMZELX sales reached EUR 1.52 billion in first-half 2026. UCB stock costs EUR 204.20 on October 13, 2026, 29.48 percent below its high.

ING set a EUR 304.00 target for UCB on September 23, 2026, implying 48.87 percent upside to the Lang & Schwarz price.
UCB lists BIMZELX sales of EUR 1.52 billion in the first half of 2026 and peak-sales guidance above EUR 7.00 billion.
UCB stock costs EUR 204.20 at Lang & Schwarz on October 13, 2026 at 1:11 p.m. CEST, 29.48 percent below the 52-week high of EUR 289.50.
UCB has a P/E ratio of 17.71 and market capitalization of EUR 38.9 billion as of October 13, 2026.

Geometrisches Bauhaus-Poster mit Kreisen, Dreiecken und dem Schriftzug BIOPHARM in Primärfarben — UCB S.A., ISIN BE0003739530, illustriert als geometrisches Bauhaus-Poster mit Sektor-Kürzel BIOPHARM und Molekülformen, Illustration mit AI erstellt.

ING set a EUR 304.00 price target for UCB on September 23, 2026, according to MarketScreener. Against the EUR 204.20 quote at Lang & Schwarz, that target lies 48.87 percent higher. UCB stock was trading at EUR 204.20 at Lang & Schwarz on October 13, 2026 at 1:11 p.m. CEST.

BIMZELX sales reach EUR 1.52 billion

UCB lists BIMZELX sales of EUR 1.52 billion in the first half of 2026 and peak-sales guidance above EUR 7.00 billion on its investor website. The sales figure gives the product a 21.71 percent share of UCB's EUR 7.00 billion peak-sales threshold, using the company's stated figures.

Stock stays below its yearly high

The EUR 204.20 quote stands EUR 5.45 above the 52-week low of EUR 198.75 and EUR 85.30 below the high of EUR 289.50. The distance to the high is 29.48 percent, while the distance to the low is 2.74 percent. UCB's market capitalization is EUR 38.9 billion and its P/E ratio is 17.71 as of October 13, 2026.

Comparison with peers

UCB: P/E 17.71, market capitalization EUR 38.9 billion.

Biogen (Nasdaq, USD): plus 1.64 percent, P/E 40.60, market capitalization USD 33.9 billion.

BB Biotech (SIX, CHF): unchanged, P/E 2.02, market capitalization CHF 2.7 billion.

What the target means for valuation

The ING target is 48.87 percent above the Lang & Schwarz quote, while UCB's P/E of 17.71 is below Biogen's 40.60 and above BB Biotech's 2.02. The comparison is based on October 13, 2026 market figures and separates UCB's euro quotation from the peers' home-market currencies.

UCB price remains near its yearly low

UCB stock was trading at EUR 204.20 at Lang & Schwarz on October 13, 2026 at 1:11 p.m. CEST. The price was EUR 5.45 above the 52-week low of EUR 198.75 and EUR 85.30 below the 52-week high of EUR 289.50.

The further course of trading is shown by the continuously updated real-time quote of UCB stock.